Cirius Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• MSDC-0602K · Metabolic / Endocrinology
  MSDC-0602K is a thiazolidinedione-class insulin sensitizer that activates mitochondrial pyruvate carrier (MPC) to improve insulin sensitivity and glucose metabolism.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cirius Therapeutics, Inc. portfolio CI brief
• Cirius Therapeutics, Inc. pipeline updates RSS